Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles

Nanoparticle (NP) drug delivery systems (5−250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biological barriers and releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating nanoparticles during systemic delivery is a critical issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life. In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation. These factors include interactions with biological barriers and tunable nanoparticle parameters, such as composition, size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization. All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.

[1]  H. Lijnen Angiogenesis and obesity. , 2008, Cardiovascular research.

[2]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[3]  Robert Langer,et al.  Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.

[4]  Robert Langer,et al.  New frontiers in nanotechnology for cancer treatment. , 2008, Urologic oncology.

[5]  Sung-Bae Kim,et al.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[6]  C. van Nostrum,et al.  Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. , 2007, Biomaterials.

[7]  Dong-Wan Kim,et al.  Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Robert Langer,et al.  Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. , 2007, Nanomedicine.

[9]  J. Homsi,et al.  Phase I Trial of Poly-l-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies , 2007, Clinical Cancer Research.

[10]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[11]  K. Higaki,et al.  Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. , 2007, International journal of pharmaceutics.

[12]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[13]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[14]  Mansoor M. Amiji,et al.  Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery , 2007, Pharmaceutical Research.

[15]  Filip Braet,et al.  Contribution of high‐resolution correlative imaging techniques in the study of the liver sieve in three‐dimensions , 2007, Microscopy research and technique.

[16]  A. Chetta,et al.  Vascular remodelling and angiogenesis in asthma: morphological aspects and pharmacological modulation. , 2007, Inflammation & allergy drug targets.

[17]  M. Amiji,et al.  Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.

[18]  Robert Langer,et al.  Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. , 2007, Biomaterials.

[19]  Christopher G Thanos,et al.  Targeted nanoparticle-based drug delivery and diagnosis , 2007, Journal of drug targeting.

[20]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[21]  S. Gopinath Methods developed for SELEX , 2006, Analytical and bioanalytical chemistry.

[22]  J. Schellens,et al.  Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.

[23]  A. Domb,et al.  PEG-PLA block copolymer as potential drug carrier: preparation and characterization. , 2006, Macromolecular bioscience.

[24]  R. Langer,et al.  Nanomedicine: developing smarter therapeutic and diagnostic modalities. , 2006, Advanced drug delivery reviews.

[25]  S Moein Moghimi,et al.  Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.

[26]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Rice,et al.  Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-Platinum Tumor-Targeting Drug Delivery System , 2006, Clinical Cancer Research.

[28]  Jianjun Cheng,et al.  Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models , 2006, Clinical Cancer Research.

[29]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[30]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[31]  Hong-Zhuan Chen,et al.  In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  Jianjun Cheng,et al.  Pharmacokinetics and biodistribution of the camptothecin–polymer conjugate IT-101 in rats and tumor-bearing mice , 2006, Cancer Chemotherapy and Pharmacology.

[33]  Catherine Shaffer Nanomedicine transforms drug delivery. , 2005, Drug discovery today.

[34]  R. Langer,et al.  Poly(Ethylene Oxide)-Modified Poly(β-Amino Ester) Nanoparticles as a pH-Sensitive System for Tumor-Targeted Delivery of Hydrophobic Drugs: Part 2. In Vivo Distribution and Tumor Localization Studies , 2005, Pharmaceutical Research.

[35]  A. Tolcher,et al.  Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas , 2005, Clinical Cancer Research.

[36]  J. Sludden,et al.  A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules , 2005, Clinical Cancer Research.

[37]  F. Izzo,et al.  Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[39]  J. L. Turner,et al.  An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. , 2005, Biomacromolecules.

[40]  K. Avgoustakis,et al.  Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.

[41]  J. Wanders,et al.  Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  K. Norrby,et al.  Increased angiogenesis in diabetes , 1990, Experientia.

[43]  S. Jeffers,et al.  Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2 , 2005 .

[44]  P. Sabbatini,et al.  Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[46]  H. Ueno,et al.  Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin , 2004, British Journal of Cancer.

[47]  K. Avgoustakis,et al.  Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. , 2004, Current drug delivery.

[48]  Nicholas A Peppas,et al.  Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. , 2004, Advanced Drug Delivery Reviews.

[49]  Tae-You Kim,et al.  Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies , 2004, Clinical Cancer Research.

[50]  D. Kerr,et al.  Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer , 2004, British Journal of Cancer.

[51]  J. Frank,et al.  Angiogenesis in multiple sclerosis: is it good, bad or an epiphenomenon? , 2004, Journal of the Neurological Sciences.

[52]  J. Kreuter,et al.  Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles , 1999, Pharmaceutical Research.

[53]  A. Hanauske,et al.  Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD) , 1993, Investigational New Drugs.

[54]  W. Stehbens,et al.  Vesicles of fenestrated and non-fenestrated endothelium , 1969, Zeitschrift für Zellforschung und Mikroskopische Anatomie.

[55]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[56]  A. Anagnostopoulos,et al.  Safety of high‐dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia , 2003, British journal of haematology.

[57]  Christilyn P. Graff,et al.  Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. , 2003, Cancer research.

[58]  D. Sane,et al.  Abnormal angiogenesis in diabetes mellitus , 2003, Medicinal research reviews.

[59]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[60]  Kazunori Kataoka,et al.  PEGylated nanoparticles for biological and pharmaceutical applications. , 2003, Advanced drug delivery reviews.

[61]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[62]  J. Bomalaski,et al.  Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. , 2002, Cancer research.

[63]  Y. Teramura,et al.  Rolling properties of rGPIBα-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions , 2002 .

[64]  O. Bourdon,et al.  Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. , 2001, Biomaterials.

[65]  Y. Sugiyama,et al.  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[66]  J. Hopewell,et al.  Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent , 2001, Human & experimental toxicology.

[67]  K. Avgoustakis,et al.  Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. , 2001, International journal of pharmaceutics.

[68]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[69]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[70]  H. Maeda The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[71]  Y Li,et al.  PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[72]  J. Schellens,et al.  Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.

[73]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[74]  Louis M Weiner,et al.  New approaches to antibody therapy , 2000, Oncogene.

[75]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[76]  S M Moghimi,et al.  Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. , 2000, Trends in biotechnology.

[77]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  C. Charnsangavej,et al.  Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor , 2000, Cancer Chemotherapy and Pharmacology.

[79]  P Couvreur,et al.  Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. , 1999, Biomaterials.

[80]  P. Couvreur,et al.  Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting , 1999 .

[81]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  L. Murray,et al.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  M D Scott,et al.  Cellular camouflage: fooling the immune system with polymers. , 1998, Current pharmaceutical design.

[84]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[85]  F. Muggia Doxil in breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  C. Conover,et al.  Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker , 1998, Cancer Chemotherapy and Pharmacology.

[87]  FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration. , 1996, Journal of the International Association of Physicians in AIDS Care.

[88]  D. Bazile,et al.  Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. , 1996, Biomaterials.

[89]  D. Fisher,et al.  Polyethylene glycol modification: relevance of improved methodology to tumour targeting. , 1996, Journal of drug targeting.

[90]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[91]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[92]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[93]  D Tomlinson,et al.  Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS. , 1994, Clinical oncology (Royal College of Radiologists (Great Britain)).

[94]  D. Predescu,et al.  Plasmalemmal vesicles represent the large pore system of continuous microvascular endothelium. , 1993, The American journal of physiology.

[95]  N. Düzguneş Targeted drug delivery. , 1992, Journal of the California Dental Association.

[96]  D. Ingber,et al.  Inhibition of angiogenesis. , 1992, Seminars in cancer biology.

[97]  R. Eisenstein Angiogenesis in arteries: review. , 1991, Pharmacology & therapeutics.

[98]  J. Scott,et al.  Searching for peptide ligands with an epitope library. , 1990, Science.

[99]  R. Jain,et al.  Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues. , 1990, Cancer research.

[100]  J. Folkman,et al.  What is the role of endothelial cells in angiogenesis? , 1984, Laboratory investigation; a journal of technical methods and pathology.

[101]  Brigham Kl Estimations of permeability properties of pulmonary capillaries (continuous endothelium). , 1980 .

[102]  K. Brigham Estimations of permeability properties of pulmonary capillaries (continuous endothelium). , 1980, The Physiologist.

[103]  U. Ryan,et al.  Fenestrated endothelium of the adrenal gland: freeze-fracture studies. , 1975, Tissue & cell.

[104]  Maia Simionescu,et al.  MORPHOMETRIC DATA ON THE ENDOTHELIUM OF BLOOD CAPILLARIES , 1974, The Journal of cell biology.

[105]  M. El-Shahawy Angiogenesis in progressive systemic sclerosis. , 1972 .

[106]  R. Siegel Angiogenesis in progressive systemic sclerosis. , 1972, The New England journal of medicine.

[107]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.